11. Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients. Issue 5 (November 2015) Authors: Bianconi, Daniela; Schuler, Alexandra; Pausz, Clemens; Geroldinger, Angelika; Kaider, Alexandra; Lenz, Heinz-Josef; Kornek, Gabriela; Scheithauer, Werner; Zielinski, Christoph C.; Pabinger, Ingrid; Ay, Cihan; Prager, Gerald W. Journal: Thrombosis research Issue: Volume 136:Issue 5(2015) Page Start: 865 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside. Issue 1 (April 2015) Authors: Wittig, Burghardt; Schmidt, Manuel; Scheithauer, Werner; Schmoll, Hans-Joachim Journal: Critical reviews in oncology/hematology Issue: Volume 94:Issue 1(2015) Page Start: 31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Microparticle‐associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. (9th February 2013) Authors: Thaler, Johannes; Ay, Cihan; Mackman, Nigel; Metz‐Schimmerl, Sylvia; Stift, Judith; Kaider, Alexandra; Müllauer, Leonhard; Gnant, Michael; Scheithauer, Werner; Pabinger, Ingrid Journal: European journal of clinical investigation Issue: Volume 43:Number 3(2013:Mar.) Page Start: 277 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. (August 2020) Authors: Bianconi, Daniela; Herac, Merima; Posch, Florian; Schmeidl, Margit; Unseld, Matthias; Kieler, Markus; Brettner, Robert; Müllauer, Leonhard; Riedl, Jakob; Gerger, Armin; Scheithauer, Werner; Prager, Gerald Journal: Therapeutic advances in medical oncology Issue: Volume 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Mode of action of maintenance immunotherapy therapy with the TLR-9 agonist MGN1703 in metastatic colorectal carcinoma: the Phase III IMPALA study. (4th November 2015) Authors: Stein, Alexander; Kapp, Kerstin; Scheithauer, Werner; Salazar, Ramon; Ducreux, Michel; Waddell, Tom; Arnold, Dirk; Tournigand, Christophe; Sobrero, Alberto; Van Cutsem, Eric; Schmidt, Manuel; Cunningham, David Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Mode of action of maintenance immunotherapy therapy with the TLR-9 agonist MGN1703 in metastatic colorectal carcinoma: the Phase III IMPALA study. Issue 2 (December 2015) Authors: Stein, Alexander; Kapp, Kerstin; Scheithauer, Werner; Salazar, Ramon; Ducreux, Michel; Waddell, Tom; Arnold, Dirk; Tournigand, Christophe; Sobrero, Alberto; Van Cutsem, Eric; Schmidt, Manuel; Cunningham, David Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. (September 2019) Authors: Scheithauer, Werner; Putora, Paul Martin; Grünberger, Birgit; Eisterer, Wolfgang; Wöll, Ewald; Prager, Gerald; Schaberl-Moser, Renate; Greil, Richard; Glatzer, Markus Journal: Therapeutic advances in gastroenterology Issue: Volume 12(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. (January 2019) Authors: Gargiulo, Piera; Dietrich, Daniel; Herrmann, Richard; Bodoky, György; Ruhstaller, Thomas; Scheithauer, Werner; Glimelius, Bengt; Berardi, Simona; Pignata, Sandro; Brauchli, Peter Journal: Therapeutic advances in medical oncology Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. (12th January 2015) Authors: Tabernero, Josep; Chiorean, E. Gabriela; Infante, Jeffrey R.; Hingorani, Sunil R.; Ganju, Vinod; Weekes, Colin; Scheithauer, Werner; Ramanathan, Ramesh K.; Goldstein, David; Penenberg, Darryl N.; Romano, Alfredo; Ferrara, Stefano; Von Hoff, Daniel D. Journal: Oncologist Issue: Volume 20:Number 2(2015) Page Start: 143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab‐Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. (12th January 2015) Authors: Tabernero, Josep; Chiorean, E. Gabriela; Infante, Jeffrey R.; Hingorani, Sunil R.; Ganju, Vinod; Weekes, Colin; Scheithauer, Werner; Ramanathan, Ramesh K.; Goldstein, David; Penenberg, Darryl N.; Romano, Alfredo; Ferrara, Stefano; Von Hoff, Daniel D. Journal: Oncologist Issue: Volume 20:Number 2(2015) Page Start: 143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗